Catabasis, Sarepta to study DMD combination

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $1.77 (40%) to $6.25 Thursday after it partnered with Sarepta Therapeutics Inc. (NASDAQ:SRPT) to study a combination treatment for Duchenne muscular dystrophy.

In a mouse model of DMD, the partners will evaluate Catabasis' edasalonexent ( CAT-1004), a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits NF-kappa B, in combination with Sarepta's exon skipping technology. Catabasis is conducting a Phase II trial of edasalonexent to treat DMD. ...